Alpha 2.0
Login Register
» Authors » Aron Popovtzer

Aron Popovtzer

Explore the profile of Aron Popovtzer including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 108
Citations 1223
Followers 0
Related Specialties
Oncology
Otorhinolaryngology
General Surgery
Top 10 Co-Authors
Aviram Mizrachi
Gideon Bachar
Rachela Popovtzer
Yuval Nachalon
Menachem Motiei
Philip Blumenfeld
Assaf Moore
Avraham Eisbruch
Thomas Shpitzer
Jacob Shvero
Published In
Head Neck
Cancers (Basel)
Laryngoscope
Front Oncol
Int J Radiat Oncol Biol Phys
Affiliations
Soon will be listed here.
Recent Articles
1.
The Role of Adjuvant Radiotherapy for Early-Stage Oral Cavity Cancer With Minor Adverse Features; A Single Institute Experience
Yosefof E, Edri N, Kurman N, Bachar G, Shpitzer T, Mizrachi A, et al.
Head Neck . 2025 Jan; PMID: 39890747
Background: The role of post-operative radiotherapy (PORT) in early-stage (T1-T2N0M0) oral tongue squamous cell carcinoma (OTSCC) with minor adverse features (MAF) including perineural invasion (PNI) and poorly differentiated carcinoma (PDC)...
2.
The Impact of Radiotherapy on the Primary Tumor in Patients with Metastatic High-Volume Castration-Sensitive Prostate Cancer: A Propensity Score Matching Analysis
Skripai A, Blumenfeld P, Krakow A, Den R, Popovtzer A, Wygoda M, et al.
Cancers (Basel) . 2025 Jan; 17(2). PMID: 39858079
Retrospective studies suggest that local radiotherapy on the prostate improves overall survival in the metastatic setting, but its benefit in patients with high-burden metastatic disease is still uncertain. We conducted...
3.
Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics
Arnon J, Dinstag G, Tirosh O, Gugel L, Kinar Y, Gottlieb T, et al.
J Immunother Cancer . 2025 Jan; 13(1. PMID: 39800380
Introduction: Immune checkpoint inhibitors (ICI) have improved outcomes in non-small cell lung cancer (NSCLC). Nevertheless, the clinical benefit of ICI as monotherapy or in combination with chemotherapy remains widely varied...
4.
Complication Rates After Mastectomy and Reconstruction in Breast Cancer Patients Treated with Hypofractionated Radiation Therapy Compared to Conventional Fractionation: A Single Institutional Analysis
Falick Michaeli T, Hatoom F, Skripai A, Wajnryt E, Allweis T, Paluch-Shimon S, et al.
Cancers (Basel) . 2025 Jan; 17(1. PMID: 39796733
Introduction: Radiation therapy plays an important role in the treatment of localized breast cancer. Hypofractionated (HF) radiation therapy has emerged as a promising alternative to conventional fractionation (CF) schedules, offering...
5.
Stereotactic implantation of diffusing alpha-emitters radiation therapy sources in the swine brain: a potential new focal therapy for brain tumors
Shoshan Y, Gomori M, Moss L, Bari S, Edery N, Den R, et al.
J Neurooncol . 2025 Jan; PMID: 39747715
Purpose: Diffusing alpha-emitters Radiation Therapy ("Alpha DaRT") is a new cancer treatment modality that employs radium-224-loaded metal sources implanted in solid tumors to disperse alpha-emitting atoms within a therapeutic "kill-zone"...
6.
Commissioning of a novel gantry-less proton therapy system
Feldman J, Pryanichnikov A, Achkienasi A, Polyansky I, Hillman Y, Raskin S, et al.
Front Oncol . 2024 Nov; 14:1417393. PMID: 39575421
Purpose: The focus of this article is to describe the configuration, testing, and commissioning of a novel gantry-less synchrotron-based proton therapy (PT) facility. Materials And Methods: The described PT system...
7.
Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial
Sigawi T, Gelman R, Maimon O, Yossef A, Hemed N, Agus S, et al.
Front Oncol . 2024 Aug; 14:1426426. PMID: 39139285
Introduction: The main obstacle in treating cancer patients is drug resistance. Lenvatinib treatment poses challenges due to loss of response and the common dose-limiting adverse events (AEs). The Constrained-disorder-principle (CDP)-based...
8.
Management of laryngeal chondroradionecrosis: A single-center experience
Levin E, Ritter A, Bachar G, Mizrachi A, Shoffel-Havakuk H, Kurman N, et al.
Head Neck . 2024 Aug; 47(1):300-308. PMID: 39138648
Background: Laryngeal chondroradionecrosis (LCRN) is a rare but severe complication of radiation therapy. The study aimed to review the management of LCRN and evaluate the clinical benefit of hyperbaric oxygen...
9.
Pelvic lymph node mapping in prostate cancer: examining the impact of PSMA PET/CT on radiotherapy decision-making in patients with node-positive disease
Furman B, Falick Michaeli T, Den R, Ben Haim S, Popovtzer A, Wygoda M, et al.
Cancer Imaging . 2024 Jul; 24(1):96. PMID: 39075567
Introduction: Prostate Specific Membrane Antigen (PSMA) imaging with Positron Emission Tomography (PET) plays a crucial role in prostate cancer management. However, there is a lack of comprehensive data on how...
10.
The Active Tumor Vaccination in Combination With CDK4/6 Inhibitor Treatment: A Case Report
Maimon O, Nisman B, Broier S, Ben-David I, Kuznetz A, Gelfand Y, et al.
Anticancer Res . 2024 Jul; 44(8):3543-3550. PMID: 39060086
Background: Current standard treatment for metastatic breast cancer (MBC) involves cyclin-dependent kinase 4/6 (CDK4/6) inhibitors with endocrine therapy, showing potential in enhancing anti-tumor immune responses. Case Report: This report details...